skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Everolimus Tablets for Oral Suspension (Code C102880)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Everolimus Tablets for Oral Suspension

Definition: Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR's cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.

Label: Everolimus Tablets for Oral Suspension

NCI Thesaurus Code: C102880 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL437183  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Afinitor Disperz
Everolimus Tablets for Oral Suspension

External Source Codes: 
PDQ Closed Trial Search ID 739586
PDQ Open Trial Search ID 739586 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C102880
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom